Purpose In post-menopausal women, high body mass index (BMI) is an established breast cancer risk factor and is associated with worse breast cancer prognosis. We assessed the associations between BMI and gene expression of both breast tumor and adjacent tissue in estrogen receptor-positive (ER+) and estrogen receptor-negative (ER−) diseases to help elucidate the mechanisms linking obesity with breast cancer biology in 519 post-menopausal women from the Nurses' Health Study (NHS) and NHSII. Methods Differential gene expression was analyzed separately in ER+ and ER− disease both comparing overweight (BMI ≥ 25 to < 30) or obese (BMI ≥ 30) women to women with normal BMI (BMI < 25), and per 5 kg/m 2 increase in BMI. Analyses controlled for age and year of diagnosis, physical activity, alcohol consumption, and hormone therapy use. Gene set enrichment analyses were performed and validated among a subset of post-menopausal cases in The Cancer Genome Atlas (for tumor) and Polish Breast Cancer Study (for tumor-adjacent). Results No gene was differentially expressed by BMI (FDR < 0.05). BMI was significantly associated with increased cellular proliferation pathways, particularly in ER+ tumors, and increased inflammation pathways in ER− tumor and ER− tumoradjacent tissues (FDR < 0.05). High BMI was associated with upregulation of genes involved in epithelial-mesenchymal transition in ER+ tumor-adjacent tissues. Conclusions This study provides insights into molecular mechanisms of BMI influencing post-menopausal breast cancer biology. Tumor and tumor-adjacent tissues provide independent information about potential mechanisms.
Introduction
High body mass index (BMI) after menopause is an established breast cancer risk factor [1, 2] . Obese post-menopausal women (BMI ≥ 30 kg/m
2 ) have about a 70% increased risk of estrogen receptor-positive (ER+) breast cancer compared to lean women, while there is less evidence suggesting BMI is associated with ER− disease [3] [4] [5] [6] . Additionally, being overweight (BMI 25-29.9 kg/m 2 ) or obese is also associated with worse prognosis in ER+ disease, but not in ER− [7] [8] [9] [10] .
Multiple biological mechanisms may underlie the link between high BMI with ER+ breast cancer risk. One well-supported mechanism is the increased estradiol concentrations produced by adipose tissue in overweight or obese post-menopausal women [11] . Exposure of estrogen-sensitive breast tissues to high estrogen levels leads to increased cellular proliferation and initiates mutation and development of breast cancer [12, 13] . Other obesity-related effects such as insulin resistance [14] , impaired adipokine production by adipocytes [15, 16] , and low-grade local inflammation [17] also may contribute to the proliferation of mammary cells and breast tumorigenesis [18] [19] [20] . On the other hand, recent investigations have identified the effect of insulin on AKT/mTOR signaling and glycolysis; obesitymediated tissue inflammatory cytokines (e.g., leptin); and obese tissue microenvironment as plausible mechanistic links between obesity and triple-negative breast cancer (i.e., an ER− disease) [21] . Given potential crosstalk between these pathways, it is important to understand the complex biology that underlies how BMI influences breast tumor growth. Previous studies have investigated tumor molecular pathways associated with obesity in breast cancer patients [16, [22] [23] [24] [25] , but did not stratify their study population by menopausal status [16] or tumor ER status [24] due to small sample sizes.
With rising obesity rates [26] , it is important to gain insights into the molecular mechanisms of BMI driving breast cancer etiology to aid screening and prevention recommendations, and identify therapeutic targets for obese patients. The overarching aim of our work was to elucidate mechanisms linking obesity with breast cancer biology in post-menopausal women. Specifically, we assessed the associations between BMI and tissue gene expression in ER+ and ER− post-menopausal breast tumors, and tumoradjacent tissues, from the Nurses' Health Study (NHS) and NHSII. Lastly, we validated our findings by using The Cancer Genome Atlas (TCGA) for tumors [27] [28] [29] and the Polish Breast Cancer Study (PBCS) for tumor-adjacent tissues [30, 31] .
Materials and methods

Study population
The Committee on the Use of Human Subjects in Research at Brigham and Women's Hospital, Boston, MA approved this study (Protocol Number: 2010P001641). The NHS and NHSII are ongoing prospective studies. The NHS was established in 1976 with 121,701 female registered nurses, aged 30-55 years, and the NHSII was established in 1989 with 116,429 female registered nurses, aged 25-42 years. The cohorts have been followed biennially by questionnaires to query exposures and ascertain newly diagnosed diseases. Participants provide information on a range of breast cancer risk factors, including dietary, lifestyle and reproductive factors, anthropometric measures, medication use, and health outcomes.
Breast cancer diagnoses were reported on biennial questionnaires or identified through death records. Written permission was obtained from participants diagnosed with breast cancer, or their next of kin, to review medical records to confirm diagnosis and extract relevant cancer information. Formalin-fixed paraffin-embedded (FFPE) breast cancer tissue blocks were requested from treating hospitals [32] . Postmenopausal women with confirmed invasive breast cancer from NHS and NHSII and tissue blocks were selected for this study (n = 577).
Body mass index and other covariates
Weight and height were reported on study questionnaires; self-reported weight and height were previously validated in the NHSII [33] . Height was obtained at enrollment while weight was updated every 2 years, starting from 1976 (NHS) or 1991 (NHSII). BMI was calculated using self-reported weight from the participant's last available questionnaire before breast cancer diagnosis (i.e., within 2-4 years of diagnosis). Other covariates such as race, BMI at age 18, age at first birth, parity, age at diagnosis, year of diagnosis, menopausal status, recent post-menopausal hormone therapy (HT), smoking, cumulative average physical activity (metabolic equivalent hours/week) [34] , and cumulative average alcohol consumption (grams/day) [28, 35] were retrieved from baseline, subsequent, or most recent NHS/NHSII questionnaires. Tumor characteristics were extracted from medical pathology reports. Immunohistochemical statuses of ER, progesterone receptor (PR), and HER2 were obtained from central review of breast tissue microarrays [32] . Differences in demographic, clinical, and other covariates across BMI categories were analyzed using Kruskal-Wallis, Fisher's exact, or Chi-squared test (R, version 3.2.1). Statistical significance was considered as p < 0.05.
RNA extraction and microarray
Multiple tissue cores of 1 or 1.5 mm were obtained from tumor and/or histologically normal tumor-adjacent tissue. Tumor-adjacent tissue was obtained greater than one centimeter from the invasive carcinoma whenever possible; a minimum of 2 mm between tumor and tumor-adjacent was permitted. Total RNA was extracted from 577 FFPE blocks for 1154 tumor and tumor-adjacent tissues. RNA samples with at least 50 ng (n = 1027) were sent for microarray using the Glue Grant Human Transcriptome Array 3.0 pre-release version (Affymetrix, Santa Clara, CA) [36] ; 127 samples comprising 10 tumors and 117 tumor-adjacent samples were excluded due to insufficient RNA. Gene expression was normalized, summarized into Log 2 values using Robust Multi-array Average (Affymetrix Power Tools (APT) v1.18.0), and annotated [36, 37] . Data quality was first evaluated using APT probeset summarization-based metrics; samples should ideally have a receiver operator characteristic (ROC) curve of > 0.8 [38] . Due to the nature of FFPE samples, we retained 888 samples with ROC AUC of > 0.55 and performed a second round of quality control using arrayQualityMetrics v3.24.0 [39] . There were 850 final microarray files comprising 478 tumor and 372 tumoradjacent tissues from 519 women.
Gene expression data were further processed by removing 195 probes associated with the Y chromosome, removing unannotated probes, selecting the most variable probe for genes that were represented by multiple probes, correcting for batch effects using a surrogate variable analysis (SVA) R package, ComBat [40], and excluding low expressing genes (< 25th percentile). The final dataset consisted of 15,369 annotated probesets of coding and non-coding RNAs. All microarray and annotation data are available at the National Center for Biotechnology Information Gene Expression Omnibus (accession number: GSE115577). Figure 1 summarizes our analyses and results of workflow and presentation. Differential gene expression was analyzed using multivariable linear regression (limma R package), controlling for age at diagnosis, year of diagnosis, physical activity, alcohol consumption, and HT use. Since only 44 (9.6%) women were current or recent smokers and this percentage was similar across BMI categories (10.9% in normal, 8.1% in overweight, and 7.3% in obese groups), we did not control for smoking in our differential gene expression analyses. Inferences were stabilized for correlated gene structures using an empirical Bayes method and corrected for multiple hypothesis testing [41] . We performed differential gene expression in ER+ or ER− disease between overweight (BMI ≥ 25 to < 30) or obese (BMI ≥ 30) women versus women with normal BMI (BMI < 25), as well as differential gene expression per 5 kg/m 2 increase in BMI. Tumor and tumor-adjacent tissues were analyzed separately. Statistical significance for differential gene expression was achieved when false discovery rate (FDR) < 0.05. There were four underweight women (BMI < 18.5) and their exclusion did not affect our results, and thus they were retained in the normal BMI group (data not shown).
Differential gene expression
Gene set enrichment
Gene set enrichment was conducted using 50 Hallmark gene sets (version 6.1; Broad Institute, Molecular Signature Database) [42] with Camera, a competitive gene set testing method which accounts for inter-gene correlation [43] .
Statistical significance for gene set enrichment was achieved when FDR < 0.05.
Validation of gene expression and gene set enrichment
We validated our results with a subset of TCGA post-menopausal women with invasive breast cancer cases (n = 120; Supplementary File 1) for tumor tissues [28] and a subset of post-menopausal participants in the PBCS (n = 108) for tumor-adjacent tissues [30, 44, 45] . Gene expression was considered validated if the gene was differentially expressed in the same direction with FDR < 0.05 in the TCGA or PBCS cohorts. Gene sets were considered validated when they were significantly enriched in the same direction (i.e., up-or down-regulated; FDR < 0.05). Our gene set enrichment results focused on validated gene sets associated with every 5 kg/m 2 increase in BMI for maximum power.
Identification of driver genes in enriched gene sets
To identify important genes contributing to the enrichment of several gene sets, we first identified common genes within biologically related gene sets (e.g., genes in both interferon (IFN) gamma response and IFN alpha response). Next, we looked at the standard gene wise differential expression of these common genes (i.e., the limma analyses). An arbitrary cut-off of p < 0.10 was applied to identify genes that were most likely contributing to the enrichment of gene sets. Please refer to Supplementary Methods for additional methodology details.
Results
Demographic, epidemiologic, and tumor characteristics of participants
The NHS/NHSII participants were mostly white with average BMI of 26.4. Of the participants with tumor samples (n = 478), paired tumor-adjacent tissues were available on 331 (69%). The characteristics of women with tumor-adjacent samples were similar to those with tumor specimens (Table 1) . ER data were missing for four tumor and three tumor-adjacent tissues. Most of our post-menopausal cases had ER+ breast cancer (80%). Obese participants had higher BMI at age 18, lower levels of physical activity, drank less alcohol, and were least likely to use HT compared to normal and overweight participants (p < 0.05; Table 1 ). Women across BMI groups had comparable tumor size, clinical grade, and lymph node status. ER− tumors were predominately clinical grades II and III, and were PR− (99%; Supplementary Table 1 ).
Comparison of NHS/NHSII participants to validation cohorts
Supplementary Tables 2 and 3 show characteristics of the previously published post-menopausal participants from TCGA [28] and PBCS. Most participants were also white females. Compared to NHS/NHSII, TCGA participants were more recently diagnosed, had higher BMI when obese (TCGA obese group BMI mean 36.0 vs. 33.9 in NHS/NHSII), and had more advanced disease (stages II/ III: TCGA 71% and NHS/NHSII 37%; stage I: TCGA 29% and NHS/NHSII 62%). TCGA participants were also less likely to use HT and tumors were less likely to be HER2 positive. PBCS post-menopausal women were younger, were diagnosed between 1999 and 2003, drank less alcohol, were less likely to use HT, were less likely to be HER2 positive, and had more advanced disease (36% of PBCS were stage I, 64% were stages II/III) compared to NHS/NHSII. Tumor with no ER data (n=4) Tumor-adjacent with no ER data (n=3) Fig. 1 Schematic workflow of data analyses using the Nurses' Health Study (NHS), The Cancer Genome Atlas (TCGA), and Polish Breast Cancer Study (PBCS) 
Gene set enrichment
In general, enriched gene sets, including multiple obesityrelated pathways regulating insulin receptor signaling and inflammation, were observed in NHS/NHSII, but only a subset was validated in TCGA or PBCS (Fig. 2) . For example, as BMI increased, the early estrogen response pathway was significantly upregulated in NHS/NHSII ER+ tumors and downregulated in NHS/NHSII ER− tumors, but these observations were not replicated.
Focusing on validated gene sets associated with increasing BMI that were common to both ER+ and ER− tumors, the E2F TARGETS pathway was significantly upregulated (FDR < 0.05; Fig. 2 ). No driver gene was common to both diseases. In ER+ tumors, higher BMI was associated with upregulation of two additional proliferation pathways (G2M CHECKPOINT and MYC TARGETS V1) and genes involved in DNA repair; a set of genes was significantly downregulated by KRAS activation (Fig. 2) . Two common driver genes, HNRNPD and SYNCRIP, contributed to the three proliferation pathways in ER+ tumors (p < 0.10; Supplementary Fig. 1A) . In addition to E2F TARGETS, higher BMI was associated with increased expression of genes associated with IFN alpha and gamma response and activated mTORC1 complex (Fig. 2) among ER− tumors. Three common driver genes, CASP8, RTP4, and IFIT3, contributed to the IFN pathways in ER− tumors ( Supplementary  Fig. 1B) .
Among tumor-adjacent tissues, BMI was associated with increased expression of genes linked to cell death and the assembly of mitotic spindles in women with ER+ and ER− diseases (Fig. 2 ), but no common driver genes were identified. There were four other validated gene sets in ER+ tumor-adjacent tissues associated with higher BMI: epithelial-mesenchymal transition, tumor necrosis factor (TNF) alpha signaling via NFKB, angiogenesis, and transforming growth factor (TGF) beta signaling (Fig. 2) . GADD45B and SAT1 contributed to the enrichment of epithelial-mesenchymal transition, TNF alpha signaling via NFKB, and apoptosis, while LUM was the driver gene for both apoptosis and angiogenesis pathways ( Supplementary  Fig. 1C ). Tumor-adjacent tissues in ER− disease displayed activated inflammation pathways including interleukin (IL) 6 and IFN gamma with increasing BMI (Fig. 2) . STAT1, STAT2, STAT3, PTPN1, PTPN2, MYD88, IRF1, and CXCL9 were the common driver genes for these two pathways (Supplementary Fig. 1D ).
ER− women with higher BMI expressed elevated IFN gamma response with eight common driver genes in both tumor and tumor-adjacent tissues (HLA-DQA1, NCOA3, CXCL9, LCP2, GZMA, SPPL2A, STAT1, and CASP4). Secondary analyses were conducted in NHS/NHSII among ER+ stage I versus stage II/III tumors, by HT use (ever/ never) among ER+ women, by excluding women with BMI ≥ 38, and by accounting for HER2 status (assessed by immunohistochemistry) in the analysis. Overall results were similar (data not shown).
Discussion
In this large study of post-menopausal women, we characterized the gene expression profiles of both breast tumor and tumor-adjacent tissues associated with higher pre-diagnosis BMI, and used two independent cohorts to validate our results in silico. No individual gene was differentially expressed by level of BMI in either the NHS/NHSII or the replication data sets. However, women with higher BMI, particularly those with ER+ tumors, had upregulation of proliferation-related gene sets. Gene sets associated with high cellular turn over were associated with higher BMI in tumor-adjacent tissues. Breast tissues of ER− women displayed elevated inflammation with increasing BMI. Our work provides further insight into the link between adiposity and breast cancer biology. Overall, higher BMI was associated with increased cellular proliferation in breast cancer. Proliferation was particularly prominent in ER+ tumors. While there was no common driver gene identified in E2F TARGETS for ER+ and ER− tumors, synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP) was one of the driver genes identified in ER+ tumors. SYNCRIP is a heterogeneous nuclear ribonucleoprotein involved in endocrine resistant and breast tumorigenesis [46] . Specifically in ER+ tumors, genes associated with KRAS activation were downregulated among women with higher BMI, providing indirect evidence that KRAS signaling is activated. The five validated gene sets in ER+ tumors collectively suggest that higher BMI in ER+ disease can lead to greater genomic instability as indicated by elevated proliferation and KRAS signaling, and in EPITHELIAL_MESENCHYMAL_TRANSITION  TNFA_SIGNALING_VIA_NFKB  INTERFERON_GAMMA_RESPONSE  COAGULATION  KRAS_SIGNALING_UP  IL2_STAT5_SIGNALING  ALLOGRAFT_REJECTION  INFLAMMATORY_RESPONSE  COMPLEMENT  IL6_JAK_STAT3_SIGNALING  G2M_CHECKPOINT  E2F_TARGETS  FATTY_ACID_METABOLISM  OXIDATIVE_PHOSPHORYLATION  KRAS_SIGNALING_DN  PANCREAS_BETA_CELLS  BILE_ACID_METABOLISM  PEROXISOME  ADIPOGENESIS  ESTROGEN_RESPONSE_EARLY  MYC_TARGETS_V2  NOTCH_SIGNALING  REACTIVE_OXIGEN_SPECIES_PATHWAY  HEME_METABOLISM  GLYCOLYSIS  APICAL_SURFACE  CHOLESTEROL_HOMEOSTASIS  UV_RESPONSE_UP  ESTROGEN_RESPONSE_LATE  SPERMATOGENESIS  WNT_BETA_CATENIN_SIGNALING  MYOGENESIS  HYPOXIA  XENOBIOTIC_METABOLISM  P53_PATHWAY  HEDGEHOG_SIGNALING  APICAL_JUNCTION  ANGIOGENESIS  UV_RESPONSE_DN  MITOTIC_SPINDLE  TGF_BETA_SIGNALING  APOPTOSIS  PROTEIN_SECRETION  UNFOLDED_PROTEIN_RESPONSE  MYC_TARGETS_V1  INTERFERON_ALPHA_RESPONSE  ANDROGEN_RESPONSE  DNA_REPAIR  PI3K_AKT_MTOR_SIGNALING response, genes involved in DNA repair may be upregulated. ER− tumors were characterized by other obesity hallmarks such as inflammation [17] and mTORC1 activation [47, 48] . In sum, our data reinforce that ER+ and ER− tumors are separate diseases with distinct biology, thus supporting previous studies that excess adiposity enhances cellular proliferation of breast tumors [16, 49, 50] and pointing to several potential mechanisms whereby being overweight or obese could be associated with worse prognosis in ER+ disease [7] [8] [9] [10] .
There was little overlap in gene sets between ER+ tumor and tumor-adjacent tissues. This may be attributed to differences in cellular composition between adjacent normal and tumor tissues, as well as changes induced by the carcinogenic process. Previous studies reported that tumor and normal breast tissues differ in their association with risk factor exposures [44] . In our study, the epithelial-mesenchymal transition gene set was enriched specifically in ER+ tumoradjacent tissues, but not in ER+ tumor tissue as reported by Fuentes-Mattei et al. [16] . Since TNF alpha signaling can influence the breast epithelial-mesenchymal transition [51] , one source of TNF may be obesity-related local inflammation [52] . Our work provides some insights into the "etiologic field effect" of BMI on ER+ tumor-adjacent tissues [53] .
Tumor characteristics are reflected in tumor-adjacent tissue; in particular, inflammation is present in both tumor and tumor-adjacent normal surrounding basal-like cancers [54] . We found that genes involved in inflammation were upregulated in both tumor and tumor-adjacent tissues of ER− women, with eight common genes driving the IFN gamma response pathway in both tissue types. This suggests that inflammation associated with BMI was more evident and robust in tissue among women with ER− disease. Collectively, obesity-related inflammation in both ER+ and ER− tumor-adjacent tissues/microenvironment may promote breast cancer aggressiveness via elevated aromatase, metabolic dysfunction, and extracellular matrix substances secreted by adipose tissues (e.g., matrix metalloproteases, chemokines, and pro-inflammatory cytokines including IL6) [55] [56] [57] [58] .
Since estrogen levels in blood and breast tissues are positively correlated with BMI [11, 59] , we expected to observe a BMI/estrogen-related pathway association in ER+ tumors. Although the estrogen pathway was significantly upregulated in the NHS/NHSII cohort, this observation was not replicated. An obesity gene signature developed by Creighton et al. also did not contain ER, PR, or other estrogen-regulated genes [24] . We did, however, observe increases in a number of proliferation-related pathways (for both ER+ and ER− tumors) and in DNA repair (ER+ tumors), which can be caused by ER signaling and estrogen metabolites [60, 61] . Clearly, the relationship between tissue estrogen signaling pathways and adiposity requires further investigation.
Fuentes-Mattei and colleagues [16] also reported that obesity accelerates ER+ breast cancer progression via adipogenesis and PI3K/AKT/mTOR signaling [16] . The PI3K/ AKT/mTOR pathway in tumors was upregulated in both NHS/NHSII and TCGA but was only statistically significant in NHS/NHSII. The smaller sample sizes and differences in ER and/or HER2 status (less ER− and/or HER2-positive cases) of the validation cohorts compared to NHS/NHSII; different tissue types (fresh frozen versus FFPE); and gene expression platforms may contribute to our inability to validate certain pathways. Our findings were generally robust in sub-analyses that made the NHS/NHSII and validation cohorts more comparable (e.g., among stage I tumors only). Overall, these differences also highlight the challenges in obtaining large, comparable, independent datasets for gene expression and pathway validation.
The strengths of our study include leveraging the large well-characterized NHS/NHSII cohorts which collected detailed epidemiologic data prior to diagnosis and we were able to control for well-known risk factors. Further, all breast cancer cases were pathologically confirmed and ER status was centrally reviewed. Given that the validation data sets had distinct population characteristics and used different technical platforms, replication represents gene sets that are likely to be robust across a range of populations and across methods.
Limitations of our study include the use of FFPE samples for microarray in NHS/NHSII, and small sample sizes for ER− cases, particularly in the validation datasets. Our FFPE samples were processed by various institutions and some FFPE blocks were over 20 years old. This resulted in lower quality RNA yield and microarray CEL files. We addressed this by performing two quality control steps and demonstrated high correlations between ESR1, PGR, and ERBB2 expression with ER, PR, and HER2 immunohistochemistry staining [28] . We were underpowered to stratify our samples by ER and HER2 simultaneously to better understand the biological effect of BMI on tumors by HER2 status. We attempted to address the imbalance in HER2 status between NHS/NHSII and the validation cohorts by accounting for HER2 in our secondary analyses. Future studies with more cases of ER− tumors and HER2 status are warranted to investigate the biological effects of ER and HER2 with BMI. Another limitation was the unknown germline BRCA1/2 status of our cases. We were unable to assess if BRCA1/2 mutation influences the association between BMI and DNA repair pathways. Our study consisted of mostly white females. Hence, replication in other ethnically diverse cohorts is warranted. Lastly, we were unable to evaluate prognostic genes associated with BMI due to limited breast cancer-specific survival events in this study population.
In summary, this study presents the largest post-menopausal breast tumor and tumor-adjacent dataset and analyses to date, and our data were independently replicated. Higher BMI was associated with higher expression of cellular proliferation pathways in breast cancer. In ER− disease, higher BMI was associated with IFN gamma pathway. Future work can include mechanistic studies to investigate how BMIassociated pathways influence post-menopausal breast etiology and identifying prognostic breast cancer genes or gene sets associated with high BMI.
